Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study

Chen, Fei; Park, Sungshim L.; Wilkens, Lynne R.; Wan, Peggy; Hart, Steven N.; Hu, Chunling; Yadav, Siddhartha; Couch, Fergus J.; Conti, David V.; Smith, Adam J. de; Haiman, Christopher A.

doi:10.1158/0008-5472.can-21-4461

Cited by 9 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Li (32). Chen et al found that germline pathogenic variants in BRCA1, BRCA2, and ERCC2 increased the risk for female breast cancer patients of developing an SPM (33). Nevertheless, no similar research had been published in MBC patients and few studies had focused on the SPM issue in MBC patients.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients: a population-based analysis

Huang

Heringa³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundMale breast cancer (MBC) is rare, which has restricted prospective research among MBC patients. With effective treatments, the prognosis of MBC patients has improved and developing a second primary malignancy (SPM) has become a life-threatening event for MBC survivors. However, few studies have focused on the prognosis of MBC patients and looked into the SPM issue in MBC survivors.MethodWe reviewed MBC patients diagnosed between 1990 and 2016 from the latest Surveillance, Epidemiology, and End Results (SEER) Plus database. Competing risk models and nomograms were conducted for predicting the risk of cancer-specific death and SPM occurrence. C-indexes, calibration curves, ROC curves, and decision curve analysis (DCA) curves were applied for validation.ResultA total of 1,843 MBC patients with complete information were finally enrolled and 60 (3.26%) had developed an SPM. Prostate cancer (40%) was the most common SPM. The median OS of all the enrolled patients was 102.41 months, while the median latency from the initial MBC diagnosis to the subsequent diagnosis of SPM was 67.2 months. The patients who suffered from an SPM shared a longer OS than those patients with only one MBC (p = 0.027). The patients were randomly divided into the development cohort and the validation cohort (at a ratio of 7:3). The Fine and Gray competing risk model was used to identify the risk factors. Two nomograms were constructed and validated to predict the 5-year, 8-year, and 10-year survival probability of MBC patients, both of which had good performance in the C-index, ROC curves, calibration plots, and DCA curves, showing the ideal discrimination capability and predictive value clinically. Furthermore, we, for the first time, constructed a nomogram based on the competing risk model to predict the 5-year, 8-year, and 10-year probability of developing an SPM in MBC survivors, which also showed good discrimination, calibration, and clinical effectiveness.ConclusionWe, for the first time, included treatment information and clinical parameters to construct a nomogram to predict not only the survival probability of MBC patients but also the probability of developing an SPM in MBC survivors, which were helpful in individual risk estimation, patient follow-up, and counseling in MBC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients: a population-based analysis

Huang

Heringa³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Second primary non-breast cancers in young breast cancer survivors

Zhang,

Brantley,

Rosenberg

et al. 2024

Breast Cancer Res Treat

View full text Add to dashboard Cite

Tumor analysis of BRCA carriers reveals genomic similarities although separated by time

Falick Michaeli,

Granit Mizrahi,

Azria

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Among the dominant pathogenic genes (PG) in breast cancer are BRCA1/2 . Knowing whether a patient carry one of these alterations is meaningful as it affects management. A substantial question is to what extent are the genomic profile of a tumor and its characteristics affected by the germline profile of BRCA1/2 and what is the possible contribution of other environmental factors. Here, we compared the molecular characteristics of two subsequent primary breast cancers in three women (6 primary breast cancers) BRCA PG carriers, and in two of them also a primary lung cancer. Comparing two different tumors in the same patient neutralizes the contribution of other germline changes, and may demonstrate possible effects of other external insults occurring between the first and second tumor. Nonetheless, epigenetic changes resulting from early life events will be present in all tumors that the patient has developed. Our analysis suggests that tumors arising from the same tissue in the same patient share similar molecular characteristics, albeit occurring in different times, as the patient is exposed to a variety of external stimuli. Supplementary Information The online version contains supplementary material available at 10.1007/s12672-024-01577-x.

show abstract

Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study

Cited by 9 publications

References 44 publications

Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients: a population-based analysis

Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients: a population-based analysis

Second primary non-breast cancers in young breast cancer survivors

Tumor analysis of BRCA carriers reveals genomic similarities although separated by time

Contact Info

Product

Resources

About